Literature DB >> 22312620

Insights on allergic rhinitis from the patient perspective.

Leonard M Fromer1, Gabriel Ortiz, Sandra F Ryan, Stuart W Stoloff.   

Abstract

Although intranasal steroid sprays are the preferred treatment of the majority of health care providers, this opinion is not carried through to patient treatment. Approximately two-thirds of adults with nasal allergy symptoms report that they use over-the-counter, nonprescription medicines, and only one-third report that they use an intranasal steroid spray. Lack of familiarity and poor patient awareness are key barriers to intranasal steroid spray use. Dissatisfaction related to side effects among users of these medications leads some of those who are familiar with intranasal steroid sprays to discontinue use after it has been prescribed. Improved health care provider–patient communication and education is a vital step toward improving the long-term management of allergic rhinitis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22312620

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  6 in total

1.  A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis.

Authors:  Anahi Yanez; Alex Dimitroff; Peter Bremner; Chae-Seo Rhee; Graham Luscombe; Barbara A Prillaman; Neil Johnson
Journal:  Allergy Rhinol (Providence)       Date:  2016-01-01

2.  Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study.

Authors:  A Simon Carney; David B Price; Pete K Smith; Richard Harvey; Vicky Kritikos; Sinthia Z Bosnic-Anticevich; Louise Christian; Derek A Skinner; Victoria Carter; Alice Ms Durieux
Journal:  Pragmat Obs Res       Date:  2017-08-30

3.  Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases.

Authors:  Pete Smith; David Price; Richard Harvey; Andrew Simon Carney; Vicky Kritikos; Sinthia Z Bosnic-Anticevich; Louise Christian; Derek Skinner; Victoria Carter; Alice Marie Sybille Durieux
Journal:  J Asthma Allergy       Date:  2017-05-09

Review 4.  Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications.

Authors:  Rosa M Muñoz-Cano; Rocio Casas-Saucedo; Antonio Valero Santiago; Irina Bobolea; Paula Ribó; Joaquim Mullol
Journal:  J Clin Med       Date:  2019-08-29       Impact factor: 4.241

5.  A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress.

Authors:  Peter W Hellings; Antonella Muraro; Wytske Fokkens; Joaquim Mullol; Claus Bachert; G Walter Canonica; David Price; Nikos Papadopoulos; Glenis Scadding; Gerd Rasp; Pascal Demoly; Ruth Murray; Jean Bousquet
Journal:  Clin Transl Allergy       Date:  2015-10-27       Impact factor: 5.871

6.  Real-life treatment of rhinitis in Australia: a historical cohort study of prescription and over-the-counter therapies for patients with and without additional respiratory disease.

Authors:  David B Price; Pete K Smith; Richard John Harvey; A Simon Carney; Vicky Kritikos; Sinthia Z Bosnic-Anticevich; Louise Christian; Derek Skinner; Victoria Carter; Alice Ms Durieux
Journal:  Pragmat Obs Res       Date:  2018-08-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.